Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
bioAffinity Technologies, Inc. - Common Stock
(NQ:
BIAF
)
1.723
-0.017 (-0.98%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bioAffinity Technologies, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer
March 28, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023
March 24, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
Why Is BioAffinity (BIAF) Stock Up 40% Today?
September 28, 2022
BioAffinity received roughly $7.7 million in warrant exercises, bringing a cash infusion to the otherwise challenged BIAF stock.
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 17, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 14, 2023
Via
Benzinga
bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications
February 13, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
Dow Rises 80 Points; Altamira Therapeutics Shares Plunge
January 24, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 80 points on Tuesday. The Dow traded up 0.24% to 33,710.06 while the NASDAQ fell 0.21% to 11,340.24. The S&P 500...
Via
Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 24, 2023
Via
Benzinga
Dow Edges Higher; Crude Oil Down 1%
January 24, 2023
U.S. stocks traded mostly flat midway through trading, with the Dow Jones trading slightly higher on Tuesday. The Dow traded up 0.03% to 33,638.42 while the NASDAQ fell 0.07% to 11,356.65. The S&P 500...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 24, 2023
Via
Benzinga
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
January 24, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
January 04, 2023
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 28, 2022
Via
Benzinga
bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench
December 15, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
December 09, 2022
Via
Benzinga
bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
December 01, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
November 30, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
November 21, 2022
Via
Benzinga
bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
November 10, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies to Report Third Quarter 2022 Financial Results
November 08, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia
October 25, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 21, 2022
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million.
Via
Benzinga
bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
October 12, 2022
From
bioAffinity Technologies, Inc.
Via
Business Wire
Why Amylyx Pharmaceuticals Is Trading Higher By Over 8%; Here Are 22 Stocks Moving Premarket
September 30, 2022
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) rose 42% to $3.21 in pre-market trading after dipping 26% on Thursday. SAI.TECH recently announced the launch of new liquid cooling Bitcoin mining...
Via
Benzinga
7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up
September 29, 2022
While these market ideas are risky, they offer enough relevance to be intriguing.
Via
InvestorPlace
Nasdaq Surges Over 150 Points; Gold Rises 2%
September 28, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Wednesday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 28, 2022
Gainers
Via
Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.